<DOC>
	<DOC>NCT01003691</DOC>
	<brief_summary>The purpose of this study is to determine the safety and tolerability of multiple doses of RN6G in subjects with advanced dry, age-related macular degeneration including geographic atrophy.</brief_summary>
	<brief_title>Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<mesh_term>Retinal Degeneration</mesh_term>
	<criteria>Be of nonchild bearing potential Diagnosis of dry AMD including uni or multifocal geographic atrophy without foveal involvement BCVA of 20/50 or better in the study eye Evidence of ocular disease other than advanced AMD or GA in the study eye History or diagnosis of exudative (wet) AMD, with subretinal or choroidal neovascular lesions in the study eye Presence of disease or condition that might compromise the cardiovascular, hematological, renal, hepatic, pulmonary, endocrine, central nervous immune, or gastrointestinal system Requires ocular or systemic medications that are known to be toxic to the lens, retina or optic nerve</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Phase 1b Advanced Dry Age-Related Macular Degeneration RN6G</keyword>
</DOC>